The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Treatment options in refractory metastatic colorectal cancer
Kathrin Heinrich, MD, Ludwig-Maximilians-Universität München, Munich, Germany, gives an overview of treatment strategies for third-line and beyond refractory metastatic colorectal cancer, focusing on various options depending on pre-treatment and molecular subtypes. These include trifluridine-tipiracil plus bevacizumab, regorafenib, and the new option of fruquintinib. For RAS wild-type patients, EGFR re-challenge is viable, and in HER2-positive cases, therapies like trastuzumab deruxtecan are considered. Molecular profiling, such as KRAS G12C analysis, will be essential to guide therapy selection. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
